Nalidixic Acid Sodium is a synthetic naphthyridone antibiotic developed by Sanofi Aventis. It is similar in structure and mechanism to quinolones, with a 1,8-naphthyridine nucleus containing 2 nitrogen atoms (unlike quinoline that contains a single nitrogen atom). It is an inhibitor of bacterial DNA polymerase and avian myeloblastoma virus reverse transcriptase. The compound can be used to study bacterial division and apoptosis research. Nalidixic Acid Sodium is sparingly soluble in water.
